Company news

Jazz Pharmaceuticals plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

June 19, 2024

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

May 31, 2024

Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024

May 29, 2024

Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer

May 28, 2024

Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism

May 21, 2024

Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference

April 30, 2024

Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance

April 30, 2024

Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

April 23, 2024

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

April 16, 2024

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

April 9, 2024

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

April 1, 2024

Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024

March 11, 2024

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance

February 27, 2024

Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors

February 26, 2024

Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer

February 20, 2024

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences

February 19, 2024

Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024

February 13, 2024

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

February 6, 2024

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder

December 20, 2023

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

December 7, 2023

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting

November 30, 2023

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

November 29, 2023

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

November 7, 2023

Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers

November 6, 2023

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences

October 31, 2023

Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023

October 24, 2023

Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Real-World, Evidence-Based Approaches for Individualized Treatment in Adul...

October 22, 2023

Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023

October 17, 2023

Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023

October 15, 2023

Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

September 20, 2023

Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences

September 12, 2023

Jazz Pharmaceuticals Announces Key Update to Leadership Team

September 11, 2023

Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023

September 10, 2023

Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference

August 23, 2023

Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance

August 8, 2023

Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023

July 25, 2023

Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

July 20, 2023

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

June 1, 2023

Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

May 30, 2023

Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference

May 29, 2023

Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023

May 24, 2023

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance

May 9, 2023

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 1, 2023

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023

April 26, 2023

Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023

April 25, 2023

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

April 18, 2023

Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health

March 29, 2023

Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline

March 14, 2023

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

February 28, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.